Benefits
Better Bioavailability than Resveratrol
Pterostilbene has 80% oral bioavailability vs ~20% for resveratrol — due to dimethylated structure resisting first-pass metabolism. Half-life ~7 hours (vs <1 hour for resveratrol). Functionally, pterostilbene may achieve and maintain therapeutic plasma levels more reliably.
Cognitive Function Support
Animal models show pterostilbene improves cognitive performance, particularly age-related cognitive decline. Riche 2014 trial in adults showed mixed mood/cognitive effects with pterostilbene + grape extract; effect modest. Mechanism: SIRT1 activation, anti-inflammatory effects, neurogenesis support.
Cardiovascular Effects
Riche 2014 trial showed pterostilbene reduced blood pressure modestly in adults with hyperlipidemia. Some evidence for cholesterol reduction. Anti-atherosclerotic mechanisms similar to resveratrol but potentially more bioavailable.
Anti-Inflammatory / Antioxidant
Reduces inflammatory markers, activates Nrf2 antioxidant pathway, modulates NF-κB. Broad anti-inflammatory profile basis for longevity applications.
SIRT1 Activation (Theoretical Longevity)
Like resveratrol, pterostilbene activates SIRT1 — sirtuin pathway involved in longevity. Better bioavailability theoretically translates to more reliable SIRT1 activation. Component of NMN/NR + sirtuin activator longevity stacks.
Mechanism of action
Resveratrol Analog with Better Pharmacokinetics
Dimethylated structure (vs resveratrol's hydroxyl groups) makes pterostilbene more lipophilic — better cell membrane penetration, slower metabolism, longer half-life. Same stilbene core mechanism with improved drug-like properties.
SIRT1 Activation
Activates SIRT1 deacetylase — relevant to longevity, mitochondrial biogenesis, glucose homeostasis. Same mechanism as resveratrol with potentially better bioavailability.
Nrf2 Antioxidant Pathway
Activates Nrf2 transcription factor, upregulating endogenous antioxidant enzymes (SOD, catalase, glutathione synthase). Adaptive antioxidant response.
PPAR-alpha Modulation
Modulates PPAR-alpha — nuclear receptor involved in lipid metabolism. May contribute to cholesterol and triglyceride effects.
Clinical trials
RCT of pterostilbene (125 mg BID) ± grape seed extract vs placebo in 80 adults with hyperlipidemia for 6-8 weeks.
80 hyperlipidemic adults.
Pterostilbene reduced blood pressure modestly; mixed lipid effects (some increase in LDL with pterostilbene alone — concerning); generally well-tolerated. Foundational human trial; results suggest pterostilbene effects are nuanced.
Phase 1 dose-finding study of pterostilbene in healthy adults — establishing pharmacokinetics, safety, tolerability up to 250 mg/day.
Healthy adults.
Pterostilbene well-tolerated up to 250 mg/day; bioavailability ~80% (vs ~20% resveratrol); half-life ~7 hours. Established safety profile and dosing range.
About this ingredient
Pterostilbene (trans-3,5-dimethoxy-4'-hydroxystilbene) is a METHYLATED ANALOG of RESVERATROL — distinguished by two methyl groups replacing two of resveratrol's hydroxyl groups. Found in BLUEBERRIES (highest natural source ~99-520 ng/g), cranberries, grapes, peanuts.
CRITICAL ADVANTAGE OVER RESVERATROL: oral bioavailability ~80% (vs ~20% for resveratrol); half-life ~7 hours (vs <1 hour for resveratrol); more lipophilic and resistant to glucuronidation/sulfation first-pass metabolism. PTEROSTILBENE BRANDED SOURCES: pTeroPure® (Sabinsa Corporation) — most clinically-studied form; standardized 99% trans-pterostilbene.
EVIDENCE-BASED USES: (1) Cardiovascular support — Riche 2014 modest BP reduction; (2) Antioxidant; (3) Anti-inflammatory; (4) Longevity stack component (SIRT1 activator); (5) Cognitive support — preclinical strong, clinical limited.
CRITICAL CAUTIONS: (1) LDL ELEVATION CONCERN — Riche 2014 noted modest LDL cholesterol INCREASE with pterostilbene alone (not with grape seed extract combination); not consistent across all trials but worth monitoring in hyperlipidemic patients; consider combining with grape seed extract or other antioxidant flavonoids to mitigate; (2) HUMAN CLINICAL DATA LIMITED — most evidence preclinical; longevity claims based largely on mechanism (SIRT1) and pharmacokinetic advantages over resveratrol rather than human outcomes; (3) ANTICOAGULANTS — theoretical bleeding risk less than resveratrol; monitor; pre-surgery discontinuation; (4) PREGNANCY/LACTATION — insufficient safety data; AVOID supplementation; dietary blueberries safe; (5) HORMONE-SENSITIVE CONDITIONS — pterostilbene has weaker phytoestrogenic effects than resveratrol but theoretical concern remains; consult oncologist; (6) PEANUT ALLERGY — pterostilbene from peanut sources may pose theoretical cross-reactivity (typically very low residual protein); (7) DOSE — 50-250 mg/day; 125 mg twice daily used in main human trial; (8) STACK PAIRING — commonly combined with NMN, NR, resveratrol, quercetin, fisetin in longevity protocols; effects may be additive; (9) RESVERATROL COMPARISON — for SIRT1/longevity applications, pterostilbene's better bioavailability is genuinely advantageous; resveratrol still has more clinical evidence overall but bioavailability limits practical effects; (10) BLUEBERRY CONSUMPTION — provides modest pterostilbene plus extensive other beneficial polyphenols; for general antioxidant goals, dietary blueberries are foundational; supplementation for those pursuing specific SIRT1/longevity goals; (11) BRYAN JOHNSON BLUEPRINT and similar protocols feature pterostilbene at 50 mg/day.